Literature DB >> 14735240

[Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and therapy].

C P Strassburg1, M P Manns.   

Abstract

Primary biliary cirrhosis represents a chronic cholestatic liver disease of unknown etiology. It primarily affects females, is associated with extrahepatic immune-mediated syndromes, shows an immunogenetic association with HLA DR8, and displays serum autoantibodies, which makes an autoimmune etiology likely. The diagnosis is reached in patients with elevated alkaline phosphatase, gamma glutamyl transferase and bilirubin levels who exhibit normal bile ducts upon ultrasound examination, and in whom specific antimitochondrial autoantibodies are detectable. Half of all PBC patients additionally show specific antinuclear autoantibodies. Immunosuppressive therapy is ineffective; steroids, transplant immunosuppressants, colchicine, d-penicillamine and methotrexate are of limited clinical benefit. Ursodeoxycholic acid has few side effects and leads to a biochemical response and a delay of disease progression in most cases. When ursodeoxycholic acid therapy is ineffective an overlap syndrome with autoimmune hepatitis can be present, which can respond to steroid treatment. The only curative option is liver transplantation which should be considered when bilirubin levels exceed 100 microM/l.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14735240     DOI: 10.1007/s00108-003-1127-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  58 in total

1.  The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study.

Authors:  Maria Leuschner; Julia Holtmeier; Hanns Ackermann; Ulrich Leuschner
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-12       Impact factor: 2.566

2.  Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.

Authors:  Renée Eugénie Poupon; Keith D Lindor; Albert Parés; Olivier Chazouillères; Raoul Poupon; E Jenny Heathcote
Journal:  J Hepatol       Date:  2003-07       Impact factor: 25.083

3.  Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.

Authors:  J Goulis; G Leandro; A K Burroughs
Journal:  Lancet       Date:  1999-09-25       Impact factor: 79.321

4.  Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.

Authors:  M Leuschner; K P Maier; J Schlichting; S Strahl; G Herrmann; H H Dahm; H Ackermann; J Happ; U Leuschner
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

5.  Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis?

Authors:  P Krzeski; W Zych; E Kraszewska; B Milewski; E Butruk; A Habior
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

Review 6.  Recurrent primary biliary cirrhosis.

Authors:  J Neuberger
Journal:  Baillieres Best Pract Res Clin Gastroenterol       Date:  2000-08

Review 7.  Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis.

Authors:  C P Strassburg; E Jaeckel; M P Manns
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-06       Impact factor: 2.566

8.  Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.

Authors:  Lawrence Serfaty; Antoine De Leusse; Olivier Rosmorduc; Benoit Desaint; Jean-Francois Flejou; Olivier Chazouilleres; Renée E Poupon; Raoul Poupon
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

9.  A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis.

Authors:  H C Bodenheimer; F Schaffner; I Sternlieb; F M Klion; S Vernace; J Pezzullo
Journal:  Hepatology       Date:  1985 Nov-Dec       Impact factor: 17.425

10.  Methotrexate therapy for primary biliary cirrhosis.

Authors:  Nancy Bach; Carol Bodian; Henry Bodenheimer; Edward Croen; Paul D Berk; Swan N Thung; Keith D Lindor; Thierry Therneau; Fenton Schaffner
Journal:  Am J Gastroenterol       Date:  2003-01       Impact factor: 10.864

View more
  3 in total

1.  [Sequelae of organ transplantation].

Authors:  S Ciesek; M Manns; C Strassburg
Journal:  Internist (Berl)       Date:  2006-03       Impact factor: 0.743

Review 2.  [Modern treatment of primary biliary cholangitis].

Authors:  C P Strassburg
Journal:  Internist (Berl)       Date:  2018-01       Impact factor: 0.743

3.  [Liver transplantation: deciding between need and donor allocation].

Authors:  C P Strassburg; T Becker; J Klempnauer; M P Manns
Journal:  Internist (Berl)       Date:  2004-11       Impact factor: 0.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.